Rigel reports preliminary Q4 revenue ~$51.3M; launches REZLIDHIA for AML

RIGEL PHARMACEUTICALS INC

Preliminary Q4 total revenue ~$51.3M including TAVALISSE $21.9M (+24% YoY) and REZLIDHIA $0.9M (launched Dec 22).
Recognized $20M milestone from Kissei for Japan PMDA approval of TAVALISSE in chronic ITP; payment expected Q1 2023.
Cash, equivalents and short-term investments ~$58.2M as of Dec 31, 2022 (vs $125.0M a year earlier).
REZLIDHIA (olutasidenib) FDA approved for R/R AML with IDH1 mutation; commercial launch underway.
First patients dosed in Phase 1b trial of R289 (IRAK1/4 inhibitor) for lower-risk MDS.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RIGEL PHARMACEUTICALS INC reported the fourth quarter ended December 31, 2022 results: revenue $51.3 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $51.3 million
Result: preliminary results

Exact text from the filing

Preliminary fourth quarter 2022 Total Revenue of approximately $51.3 million

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-002074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.